Total Payments
$20,399
2024 Payments
$13,293
Companies
9
Transactions
35
Medicare Patients
2,762
Medicare Billing
$397,417
Payment Breakdown by Category
Other$9,983 (48.9%)
Consulting$6,963 (34.1%)
Travel$2,354 (11.5%)
Food & Beverage$990.71 (4.9%)
Education$108.83 (0.5%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $9,633 | 3 | 47.2% |
| Consulting Fee | $6,963 | 2 | 34.1% |
| Travel and Lodging | $2,354 | 7 | 11.5% |
| Food and Beverage | $990.71 | 20 | 4.9% |
| Honoraria | $350.00 | 2 | 1.7% |
| Education | $108.83 | 1 | 0.5% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Gilead Sciences, Inc. | $17,542 | 20 | $0 (2024) |
| AstraZeneca Pharmaceuticals LP | $1,943 | 1 | $0 (2024) |
| Athenex Pharmaceutical Division, LLC | $350.00 | 2 | $0 (2021) |
| Novartis Pharmaceuticals Corporation | $187.09 | 3 | $0 (2024) |
| BeiGene USA, Inc. | $124.99 | 5 | $0 (2024) |
| Lilly USA, LLC | $108.83 | 1 | $0 (2022) |
| Stemline Therapeutics Inc. | $94.79 | 1 | $0 (2023) |
| PharmaEssentia USA Corporation | $29.64 | 1 | $0 (2023) |
| Merck Sharp & Dohme Corporation | $19.16 | 1 | $0 (2018) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $13,293 | 17 | Gilead Sciences, Inc. ($11,140) |
| 2023 | $6,628 | 14 | Gilead Sciences, Inc. ($6,402) |
| 2022 | $108.83 | 1 | Lilly USA, LLC ($108.83) |
| 2021 | $175.00 | 1 | Athenex Pharmaceutical Division, LLC ($175.00) |
| 2020 | $175.00 | 1 | Athenex Pharmaceutical Division, LLC ($175.00) |
| 2018 | $19.16 | 1 | Merck Sharp & Dohme Corporation ($19.16) |
All Payment Transactions
35 individual payment records from CMS Open Payments — Page 1 of 2
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/30/2024 | Gilead Sciences, Inc. | Trodelvy (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $1,820.00 | General |
| Category: ONC | ||||||
| 12/12/2024 | Novartis Pharmaceuticals Corporation | KISQALI (Drug) | Food and Beverage | In-kind items and services | $88.29 | General |
| Category: Oncology | ||||||
| 12/12/2024 | Novartis Pharmaceuticals Corporation | KISQALI (Drug) | Food and Beverage | In-kind items and services | $49.67 | General |
| Category: Oncology | ||||||
| 12/10/2024 | Gilead Sciences, Inc. | — | Food and Beverage | In-kind items and services | $83.92 | General |
| 10/24/2024 | Gilead Sciences, Inc. | Trodelvy (Drug) | Food and Beverage | In-kind items and services | $21.89 | General |
| Category: ONC | ||||||
| 10/24/2024 | Gilead Sciences, Inc. | Trodelvy (Drug) | Food and Beverage | In-kind items and services | $16.96 | General |
| Category: ONC | ||||||
| 09/18/2024 | Gilead Sciences, Inc. | Trodelvy (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $6,170.00 | General |
| Category: ONC | ||||||
| 09/08/2024 | Gilead Sciences, Inc. | Trodelvy (Drug) | Food and Beverage | In-kind items and services | $35.60 | General |
| Category: ONC | ||||||
| 09/07/2024 | Gilead Sciences, Inc. | Trodelvy (Drug) | Travel and Lodging | In-kind items and services | $462.52 | General |
| Category: ONC | ||||||
| 09/07/2024 | Gilead Sciences, Inc. | Trodelvy (Drug) | Travel and Lodging | In-kind items and services | $431.28 | General |
| Category: ONC | ||||||
| 09/07/2024 | Gilead Sciences, Inc. | Trodelvy (Drug) | Travel and Lodging | In-kind items and services | $329.22 | General |
| Category: ONC | ||||||
| 09/05/2024 | Gilead Sciences, Inc. | Trodelvy (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $1,642.50 | General |
| Category: ONC | ||||||
| 09/02/2024 | AstraZeneca Pharmaceuticals LP | — | Consulting Fee | Cash or cash equivalent | $1,942.50 | General |
| 08/15/2024 | BeiGene USA, Inc. | BRUKINSA (Drug) | Food and Beverage | In-kind items and services | $23.73 | General |
| Category: Oncology | ||||||
| 05/06/2024 | BeiGene USA, Inc. | BRUKINSA (Drug) | Food and Beverage | In-kind items and services | $24.57 | General |
| Category: Oncology | ||||||
| 03/25/2024 | BeiGene USA, Inc. | BRUKINSA (Drug) | Food and Beverage | In-kind items and services | $23.79 | General |
| Category: Oncology | ||||||
| 03/20/2024 | Gilead Sciences, Inc. | Trodelvy (Drug) | Food and Beverage | In-kind items and services | $126.14 | General |
| Category: ONC | ||||||
| 12/16/2023 | BeiGene USA, Inc. | BRUKINSA (Drug) | Food and Beverage | In-kind items and services | $29.13 | General |
| Category: Oncology | ||||||
| 12/07/2023 | Gilead Sciences, Inc. | — | Food and Beverage | In-kind items and services | $136.21 | General |
| 12/07/2023 | Novartis Pharmaceuticals Corporation | KISQALI (Drug) | Food and Beverage | In-kind items and services | $49.13 | General |
| Category: Oncology | ||||||
| 11/17/2023 | BeiGene USA, Inc. | BRUKINSA (Drug) | Food and Beverage | In-kind items and services | $23.77 | General |
| Category: Oncology | ||||||
| 06/28/2023 | Stemline Therapeutics Inc. | Orserdu (Drug) | Food and Beverage | In-kind items and services | $94.79 | General |
| Category: Oncology | ||||||
| 06/01/2023 | Gilead Sciences, Inc. | Trodelvy (Drug) | Travel and Lodging | In-kind items and services | $120.00 | General |
| Category: ONC | ||||||
| 06/01/2023 | Gilead Sciences, Inc. | Trodelvy (Drug) | Food and Beverage | In-kind items and services | $34.99 | General |
| Category: ONC | ||||||
| 05/03/2023 | Gilead Sciences, Inc. | Trodelvy (Drug) | Consulting Fee | Cash or cash equivalent | $5,020.00 | General |
| Category: ONC | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 30 | 907 | 5,839 | $1.3M | $140,986 |
| 2022 | 19 | 624 | 1,596 | $648,319 | $83,264 |
| 2021 | 21 | 665 | 2,569 | $684,367 | $90,255 |
| 2020 | 22 | 566 | 3,951 | $544,980 | $82,912 |
Total Patients
2,762
Total Services
13,955
Medicare Billing
$397,417
Procedure Codes
92
All Medicare Procedures & Services
92 procedure records from CMS Medicare Utilization — Page 1 of 4
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| J0897 | Injection, denosumab, 1 mg | Office | 2023 | 11 | 1,500 | $142,500 | $28,038 | 19.7% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 134 | 266 | $228,228 | $26,878 | 11.8% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2023 | 47 | 121 | $116,160 | $18,788 | 16.2% |
| 96413 | Administration of chemotherapy into vein, 1 hour or less | Office | 2023 | 46 | 136 | $145,773 | $16,425 | 11.3% |
| J9394 | Injection, fulvestrant (fresenius kabi) not therapeutically equivalent to j9395, 25 mg | Office | 2023 | 13 | 520 | $231,400 | $8,480 | 3.7% |
| 96365 | Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less | Office | 2023 | 49 | 109 | $41,931 | $6,325 | 15.1% |
| 99223 | Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes | Facility | 2023 | 35 | 35 | $46,200 | $5,198 | 11.3% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2023 | 27 | 27 | $36,720 | $4,780 | 13.0% |
| 96417 | Administration of additional new drug or substance into vein, 1 hour or less | Office | 2023 | 19 | 67 | $41,540 | $4,000 | 9.6% |
| Q5106 | Injection, epoetin alfa-epbx, biosimilar, (retacrit) (for non-esrd use), 1000 units | Office | 2023 | 11 | 530 | $23,850 | $3,152 | 13.2% |
| 96366 | Infusion into a vein for therapy, prevention, or diagnosis, each additional hour | Office | 2023 | 14 | 121 | $18,150 | $2,281 | 12.6% |
| 99232 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | Facility | 2023 | 14 | 29 | $13,630 | $1,967 | 14.4% |
| 96367 | Infusion into a vein for therapy, prevention, or diagnosis, additional sequential infusion, 1 hour or less | Office | 2023 | 24 | 74 | $35,150 | $1,961 | 5.6% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2023 | 13 | 13 | $14,105 | $1,903 | 13.5% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 20 | 24 | $12,192 | $1,835 | 15.1% |
| 96402 | Administration of hormonal anti-neoplastic chemotherapy under skin or into muscle | Office | 2023 | 16 | 59 | $15,974 | $1,767 | 11.1% |
| 85025 | Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count | Office | 2023 | 98 | 218 | $12,644 | $1,654 | 13.1% |
| 96375 | Injection of additional new drug or substance into vein | Office | 2023 | 31 | 107 | $26,215 | $1,531 | 5.8% |
| 96372 | Injection of drug or substance under skin or into muscle | Office | 2023 | 45 | 91 | $10,959 | $1,072 | 9.8% |
| 96360 | Infusion into a vein for hydration, 31-60 minutes | Office | 2023 | 12 | 24 | $7,058 | $731.52 | 10.4% |
| J3489 | Injection, zoledronic acid, 1 mg | Office | 2023 | 17 | 98 | $47,726 | $597.37 | 1.3% |
| 96415 | Administration of chemotherapy into vein, each additional hour | Office | 2023 | 12 | 21 | $11,550 | $548.00 | 4.7% |
| 36415 | Insertion of needle into vein for collection of blood sample | Office | 2023 | 31 | 47 | $1,175 | $394.80 | 33.6% |
| J2469 | Injection, palonosetron hcl, 25 mcg | Office | 2023 | 12 | 370 | $35,150 | $321.64 | 0.9% |
| J7050 | Infusion, normal saline solution, 250 cc | Office | 2023 | 64 | 256 | $2,560 | $129.42 | 5.1% |
About Dr. Aashini Master, D.O
Dr. Aashini Master, D.O is a Hematology & Oncology healthcare provider based in Beverly Hills, California. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 06/02/2009. The National Provider Identifier (NPI) number assigned to this provider is 1154557387.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Aashini Master, D.O has received a total of $20,399 in payments from pharmaceutical and medical device companies, with $13,293 received in 2024. These payments were reported across 35 transactions from 9 companies. The most common payment nature is "Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program" ($9,633).
As a Medicare-enrolled provider, Master has provided services to 2,762 Medicare beneficiaries, totaling 13,955 services with total Medicare billing of $397,417. Data is available for 4 years (2020–2023), covering 92 distinct procedure/service records.
Ad
Practice Information
- Specialty Hematology & Oncology
- Other Specialties Internal Medicine
- Location Beverly Hills, CA
- Active Since 06/02/2009
- Last Updated 01/16/2020
- Taxonomy Code 207RH0003X
- Entity Type Individual
- Practice Solo Practitioner
- NPI Number 1154557387
Products in Payments
- Trodelvy (Drug) $17,322
- KISQALI (Drug) $187.09
- BRUKINSA (Drug) $124.99
- VERZENIO (Drug) $108.83
- Orserdu (Drug) $94.79
- BESREMI (Drug) $29.64
- KEYTRUDA (Biological) $19.16
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Hematology & Oncology Doctors in Beverly Hills
Dr. Noam Drazin, M.d, M.D
Hematology & Oncology — Payments: $1.7M
Hematology & Oncology $1.7M
Linnea Chap, M.d, M.D
Hematology & Oncology — Payments: $691,173
Hematology & Oncology $691,173
Dr. Marina Vaysburd, M.d, M.D
Hematology & Oncology — Payments: $133,758
Hematology & Oncology $133,758
Dr. Barry Rosenbloom, M.d, M.D
Hematology & Oncology — Payments: $106,674
Hematology & Oncology $106,674
Dr. Afshin Gabayan, M.d, M.D
Hematology & Oncology — Payments: $54,070
Hematology & Oncology $54,070
Howard Yeh, Md, MD
Hematology & Oncology — Payments: $22,388
Hematology & Oncology $22,388